Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Tom Godfrey
OM

Tom Godfrey

Ord Minnett
Wall Street Analyst
★★★☆☆
#2020
on 13Foresight · ranked by our own returns
45%
Success Rate
-0.1%
Average Return
14 of 31 calls profitable · -2.2% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 45% of Tom Godfrey's ratings turned a profit when each position was held for 1 year — averaging -0.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

51 Buy 6 Hold 3 Sell
Tom's Stock Coverage 12 ratings · 2026-11-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AU:ACL
Australian Clinical Labs Ltd
 Oct 30, 2026 HOLD Hold
-13.5% avg upside
6 analysts
$3.00
9.19% Downside
 +0.0% ·
AU:IDX
Integral Diagnostics Ltd.
 Oct 30, 2026 BUY Strong Buy
+62.9% avg upside
12 analysts
$2.70
52.94% Upside
 · ·
AU:TRJ
Trajan Group Holdings Ltd
 Oct 29, 2026 BUY Strong Buy
+233.3% avg upside
3 analysts
$0.60
139.95% Upside
 +0.0% ·
AU:AYA
Artrya Limited
 Oct 27, 2026 BUY Strong Buy
+87.1% avg upside
3 analysts
$7.00
152.75% Upside
 +7.9% ·
AU:SIG
Sigma Healthcare Ltd
 Oct 22, 2026 BUY Strong Buy
+128.2% avg upside
10 analysts
$3.20
17.13% Upside
 +0.0% ·
AU:EIQ
EchoIQ Limited
 Sep 30, 2026 BUY Strong Buy
+192.5% avg upside
1 analyst
$1.55
192.50% Upside
 -10.5% ·
AU:REG
Regis Healthcare Ltd.
 Sep 03, 2026 HOLD Buy
-0.7% avg upside
6 analysts
$6.00
24.94% Upside
 +9.2% ·
AU:MVF
Monash IVF Group Ltd
 Sep 01, 2026 BUY Buy
+35.6% avg upside
7 analysts
$0.85
18.13% Upside
 -1.6% ·
AU:PGC
Paragon Care Limited
 Aug 27, 2026 BUY Strong Buy
+93.6% avg upside
1 analyst
$0.30
93.57% Upside
 +12.7% ·
AU:VFY
Vitrafy Life Sciences Ltd.
 Aug 14, 2026 BUY Strong Buy
+116.9% avg upside
2 analysts
$5.00
120.21% Upside
 -46.6% ·
AU:4DX
4DMedical Ltd
 Jun 03, 2026 SELL Hold
+12.8% avg upside
2 analysts
$3.00
23.04% Upside
 +33.7% ·
AU:IPD
Impedimed Limited
 May 12, 2026 BUY Strong Buy
+2150.0% avg upside
5 analysts
$0.02
399.98% Upside
 -50.0% ·
🔒 7 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Tom Godfrey — Frequently Asked Questions
How accurate are Tom Godfrey's stock ratings?
Based on the calls 13Foresight could measure, about 45% of Tom's ratings were profitable over a one-year hold, with an average return of -0.1% per rating, or -3.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Tom ranked on 13Foresight?
Tom Godfrey is currently ranked #2020 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Tom cover?
Tom most recently has ratings on AU:ACL, AU:IDX, AU:TRJ, AU:AYA, AU:SIG, AU:EIQ, AU:REG, AU:MVF, AU:PGC, AU:VFY, AU:4DX, AU:IPD. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.